Resectable Pancreatic Ductal Adenocarcinoma
generalPancreatic ductal adenocarcinoma amenable to surgical resection.
9
Centers
11
Active Trials
$1.6B
Cancer Funding
Specific Cancer Types(2)
Top Centers for Resectable Pancreatic Ductal Adenocarcinoma(9)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Winship Cancer InstituteAtlanta, GA NCI Comprehensive Active Research Program | 68.1 |
| 2 | OHSU Knight Cancer InstitutePortland, OR NCI Comprehensive Active Research Program | 68.1 |
| 3 | BC CancerVancouver, BC Active Research Program | 68.1 |
| 4 | UCLA Jonsson Comprehensive Cancer CenterLos Angeles, CA NCI Comprehensive | 45.6 |
| 5 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive | — |
| 6 | NCI Comprehensive | — |
| 7 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive | — |
| 8 | Karmanos Cancer InstituteDetroit, MI NCI Comprehensive | — |
| 9 | Northwell Health Cancer InstituteNew York, NY | — |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →